Beta-2-glycoprotein I antibodies in patients with thrombosis

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 63, Issue 2, 2003, Pages 111-118

  Ebeling, Freja ^a,c   Pettersson, T ^b   Muukkonen, L ^a   Vahtera, E ^a   Rasi, V ^a  

^a FINNISH RED CROSS BLOOD SERVICE   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c NONE   (Finland)

Author keywords

Antiphospholipid antibodies; Arterial thrombosis; Beta 2 glycoprotein; Cardiolipin; Lupus anticoagulant; Stroke; Thrombophilia; Venous thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; BIOLOGICAL MARKER; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; LUPUS ANTICOAGULANT;

ADOLESCENT; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BRAIN ISCHEMIA; CHILD; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; MALE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; SAMPLING; THROMBOCYTOPENIA; VEIN THROMBOSIS;

EID: 0038216580     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510310002086     Document Type: Article

References (33)

1. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein 1 (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
2. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7.
3. Puurunen M, Vaarala O, Julkunen H, Aho K, Palosuo T. Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1996; 80: 16-22.
4. 2-glycoprotein 1 antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies. J Lab Clin Med 1997; 129: 499-506.
5. Arnout J, Vermylen J. Mechanism of action of beta-2-glycoprotein 1-dependent lupus anticoagulants. Lupus 1998; 7 Suppl 2: S23-8.
6. 2glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. J Rheumatol 1998; 25: 667-74.
7. Voss A, Jacobsen S, Heegaard NH. Association of beta-2-glycoprotein I IgG and IgM antibodies with thrombosis and thrombocytopenia. Lupus 2001; 10: 533-8.
8. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-63.
9. Jouhikainen T, Julkunen H, Vaarala O, Leirisalo-Repo M, Stephansson E, Vahtera E, Palosuo T, Myllylä G. Antiphospholipid antibodies and thrombosis in systemic lupus erythematosus: comparison of three lupus anticoagulant assays and anticardiolipin ELISA in 188 patients. Blood Coag Fibrinol 1992; 3: 407-14.
10. Erickson EN Jr, Najmey SS, Keil LB, El-Kadi HS, DeBari VA. Reference calibrators for IgG antibodies to beta-2-glycoprotein I: preparation, properties and availability to investigators. Clin Chem 1996; 42: 1116-7.
11. Lewis S, Keil LB, Binder WL, DeBari VA. Standardized measurement of major immunoglobulin class (IgG, IgA, and IgM) antibodies to beta-2-glycoprotein I in patients with antiphospholipid syndrome. J Clin Lab Anal 1998; 12: 293-7.
12. Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol 1986; 41: 8-15.
13. 2-glycoprotein-1 assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. Br J Haematol 1995; 91: 471-3.
14. Vila P, McHernández MC, López-Fernández MF, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994; 72: 209-13.
15. Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109: 704-15.
16. Guglielmone H, Vitozzi S, Elbarcha O, Fernandez E. Cofactor dependence and isotype distribution of anticardiolipin antibodies in viral infections. Ann Rheum Dis 2001; 60: 500-4.
17. Myers B, Dolan G, Gould J. Audit of laboratory investigation of antiphospholipid syndrome. Br J Haematol 2001; 115: 229.
18. Hörkkö S, Olee T, Mo L, ym. Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both beta(2)-glycoprotein 1 and oxidized low-density lipoprotein. Circulation 2001; 103: 941-6.
19. Cabral AR, Amigo MC, Cabiedes J, Alarcon-Segovia D. The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta-2-glycoprotein-1 but no antibodies detectable m standard antiphospholipid assays. Am J Med 1996; 101: 472-81.
20. Silver RM, Porter TF, van Leeuween I, Jeng G, Scott JR, Branch DW. Anticardiolipin antibodies: clinical consequences of "low titers". Obstet Gynecol 1996; 87: 494-500.
21. Finazzi G, Brancaccio V, Moia MYM. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100: 318-9.
22. Abuaf N, Meyer O, Laperche S, ym. Report of the first French anticardiolipin antibodies standardization workshop. Clin Rev Allergy Immunol 1995; 13: 25-38.
23. Ginsberg JS, Wells PS, Brill-Edwards P, ym. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-91.
24. D'Angelo A, Sara O, Crippa L, Garlando A, Sabbadini MG, D'Angelo S. Relationship of lupus anticoagulant, anticardiolipin, anti-beta2-GPI and anti-prothrombin antibodies with history of thrombosis in patients with the clinical suspicion of APA-syndrome. Thromb Haemost 1997; 78: 967-8.
25. Galli M. Which antiphospholipid antibodies should be measured in the antiphospholipid syndrome? Haemostasis 2000; 30 Suppl 2: 57-62.
26. Jennings I, Kitchen S, Woods TA, Preston FE, Greaves M. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thromb Haemost 1997; 77: 934-7.
27. Jouhikainen T. Detection of lupus anticoagulant by means of dilute Russell's viper venom time is affected by oral anticoagulant therapy. Blood Coag Fibrinol 1990; 1: 627-32.
28. Guerin J, Feighery C, Sim RB, Jackson J. Antibodies to beta-2-glycoprotein 1 - a specific marker for the antiphospholipid syndrome. Clin Exp Immunol 1997; 109: 304-9.
29. Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CL, Kittner SJ. Beta(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischaemic stroke and myocardial infarction: the Honolulu Heart Program. Stroke 2001; 32: 1701-6.
30. Wilson WA, Gharavi AE, Pierre JC. International classification criteria for antiphospholipid syndrome: synopsis of a post-conference workshop held at the Ninth International (Tours) aPL Symposium. Lupus 2001; 10: 457-60.
31. Reber G, Schousboe I, Tincani A, Sanmarco M, Kveder T, de Moerloose P, Boffa M-C, Arvieux J. Inter-laboratory variability of anti-β2-glycoprotein 1 measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost 2002; 88: 66-73.
32. Bick RL, Baker WF. Antiphospholipid syndrome and thrombosis. Semin Thromb Hemost 1999; 25: 333-50.
33. Tektonidou MG, Ioannidis JPA, Boki KA, Vlachoyiannopoulos PG, Moutsopoulos HM. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. Q J Med 2000; 93: 523-30.